search
immunotherapy
Trends
- 1UConn Health Launches CAR-T Cell Therapy Program▼UConn Health Launches Cutting-Edge CAR-T Cell Therapy Program
UConn Health has announced the launch of a new CAR-T cell therapy program, a form of immunotherapy that engineers a patient's own immune cells to fight cancer. The initiative brings an advanced, personalised cancer treatment to the Connecticut institution, expanding access for patients in the region who previously had to travel elsewhere for such therapy.
- 2Eric Deutsch on the Fast-Growing Science Linking Radiation Oncology and Immunology▼Eric Deutsch: The Science Is Expanding Fast at the Interface of Radiation Oncology, Immunology, and Technology
Radiation oncology expert Eric Deutsch says science is expanding rapidly at the intersection of radiation therapy, immunology, and technology, as combined approaches such as radiotherapy paired with immunotherapy gain ground in cancer treatment. His remarks highlight how technological advances and immune-based research are reshaping how clinicians think about radiation's role beyond tumour destruction.
- 3Immunotherapy startup Adecto shuts down, blaming risk-averse funding▼Immmunotherapy startup Adecto blames ‘risk-adverse funding environment’ for closing down
Immunotherapy startup Adecto has closed down, with the company pointing to a 'risk-adverse funding environment' as the reason for its collapse. The closure underscores growing pressure on early-stage biotech firms as investors pull back from risky drug development bets, raising concerns about how many promising treatments may stall for lack of capital.
- 4SITC highlights precision immunotherapy, neoantigens, spatial biology and AI advances▼Opportunity to Explore Advances in Precision Immunotherapy, Neoantigens, Spatial Biology and AI in IO - SITC
The Society for Immunotherapy of Cancer is spotlighting opportunities to explore the latest advances in precision immunotherapy, including neoantigens, spatial biology and artificial intelligence applied immuno-oncology. The announcement points to sessions or programming where researchers and clinicians can examine how these fast-moving fields are reshaping cancer treatment. Interest centres on how AI and spatial tools are accelerating personalised cancer immunotherapy.
- 5Michigan State Medical Society Hosts Medicine History and Cuba Cancer Event●MSMS Hosts State of MSMS, History of Medicine, Cancer Immunotherapy from Cuba
The Michigan State Medical Society held an event combining its annual State of MSMS address with sessions on the history of medicine and cancer immunotherapy developments from Cuba. The programme highlighted Cuban research into lung cancer immunotherapy, an area where the country has developed its own vaccines and treatments and drawn international interest.
- 6New synthetic lethal drug targets microsatellite instability cancers▼A synthetic lethal drug for microsatellite instability cancers
Researchers have reported the development of a synthetic lethal drug aimed at cancers with microsatellite instability, a genetic feature found in colorectal and other tumor types. Synthetic lethality exploits mutations unique to cancer cells, sparing healthy tissue. The work was published in Nature, and scientists say such drugs could expand treatment options for patients whose tumors resist existing immunotherapies.
- 7AI Designs Working T-Cell Receptors for Immunotherapy Screening●AI Designs Working T-Cell Receptors That Could Transform Immunotherapy Screening
Researchers report that artificial intelligence has successfully designed functional T-cell receptors, a breakthrough that could speed up screening for immunotherapies. The AI-generated receptors are said to work in practice, suggesting machine learning can help engineer immune-cell treatments more quickly than traditional lab methods. The development is drawing attention for its potential to accelerate cancer immunotherapy research.
- 8
New coverage from Technology Networks examines efforts to design improved agonistic antibodies, drugs that activate immune-cell receptors to help the body attack tumours. The piece outlines how engineering strategies aim to enhance their potency and safety for cancer immunotherapy, a fast-growing field where several agonistic antibody candidates have struggled to show clinical benefit so far.